Brand Engagement Network has launched Cataneo's U.S. market expansion following its acquisition of Cataneo GmbH on June 30, 2026. The company established a U.S. commercial headquarters in New York City to scale Cataneo's globally proven media technology platform. This expansion integrates Cataneo's media infrastructure with Brand Engagement Network's artificial intelligence capabilities to target broadcasters, media companies, and advertising organizations seeking to modernize operations.

Strategic Expansion and Leadership

To accelerate the U.S. expansion, Brand Engagement Network appointed Don Durand as Chief Sales Officer of Cataneo. Durand brings over 20 years of experience in media technology, having held senior leadership roles at WideOrbit and Imagine Communications. He will lead Cataneo's global commercial strategy and expansion, leveraging his industry relationships to drive adoption of the company's AI-powered media technology platform.

Christian Unterseer, Cataneo Co-Founder, has joined Brand Engagement Network's Board of Directors. Unterseer founded Cataneo more than 25 years ago with a vision for cloud-based media operations. He will help drive corporate strategy and future M&A initiatives as the company advances its AI-powered media technology platform.

Platform Capabilities and Market Opportunity

Cataneo's MYDAS platform currently manages more than €6 billion in annual advertising inventory across more than 1,000 media brands and 200+ channels globally. The U.S. market presents a significant growth opportunity as media organizations seek to adopt AI-powered technologies to improve operational efficiency.

The company plans to combine Cataneo's operational platform with Brand Engagement Network's Engagement Language Model (ELM™). This integration aims to enable AI-enhanced capabilities across advertising sales, scheduling, forecasting, workflow automation, and customer engagement.

Key Expansion Details

Tyler Luck, Co-Founder and Chief Executive Officer of Brand Engagement Network, stated that the combination of Cataneo's enterprise media technology and the company's artificial intelligence capabilities creates a unique opportunity to help media organizations modernize operations and automate complex workflows.

Brand Engagement Network, Inc. (NASDAQ: BNAI), Grupo Skye, and KNOBLOCH Information Group advanced Skye Salud to Phase 2 of its clinical evaluation program in Mexico to expand testing for primary care doctors. The AI-powered medical evidence platform leverages trusted medical literature, clinical guidelines, and other authoritative sources to support evidence-based clinical information retrieval. This expansion aims to evaluate how AI-powered access to trusted medical evidence may help improve access to clinical information across healthcare settings in Mexico and Latin America.

Skye Salud was developed through a collaboration among Brand Engagement Network, Grupo Skye, and KNOBLOCH Information Group. The initiative combines Brand Engagement Network's enterprise-grade AI capabilities, Grupo Skye's leadership in AI innovation across Latin America, and KNOBLOCH Information Group's presence within Mexico's healthcare community.

Phase 1 and Phase 2 Evaluation

The Phase 2 evaluation follows the successful completion of Phase 1 rheumatology testing conducted in a controlled evaluation environment. The initial assessment evaluated platform performance across specialty-specific clinical scenarios, evidence traceability, response quality, and source transparency. Phase 1 rheumatology testing was conducted under the guidance of Dr. Ruy Carrasco, Chief Medical Information Officer of Skye Salud and BEN Board Member.

Building on those results, the Phase 2 evaluation will expand testing into primary care use cases. The platform will be assessed across a broader range of clinical topics and physician information needs. The expanded evaluation includes Spanish-language clinical content optimized for the Mexican healthcare environment.

Strategic Objectives

Mexico represents one of the largest healthcare markets in Latin America, creating a significant opportunity to evaluate AI-enabled access to trusted medical evidence at scale. The expansion of the evaluation program into primary care is intended to provide additional insight into platform performance, content coverage, usability, and future development opportunities.

The initiative reflects Brand Engagement Network's broader strategy of developing governed, enterprise-grade AI solutions for regulated industries where accuracy, transparency, accountability, and human engagement are critical. Subject to future evaluation results, regulatory considerations and commercial agreements, the organizations may explore opportunities to broaden clinical coverage and expand Spanish-language medical content.